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| INTRODUC TI ON
PanCancer genome analysis has provided important information, including on tumorigenic mechanisms, actionable genetic alterations to select molecular-targeted drugs, tumor mutation burden (TMB) to select immune checkpoint inhibitors (ICIs), hereditary cancer syndromes and clonal hematopoiesis. [1] [2] [3] [4] [5] [6] [7] Racial and ethnic population-specific cancer driver alterations and single nucleotide polymorphisms (SNPs) may complicate the evaluation and interpretation of the results of genetic analyses. Several studies have reported obvious racial differences in cancer-specific driver alterations among Japanese individuals. [8] [9] [10] Furthermore, 15% of SNPs are reportedly specific to Japanese individuals, 11 thus affecting the evaluation of the clinical significance of genetic alterations. Therefore, for accurate annotation of these genetic aberrations, race-specific analysis pipelines are required.
In the present study, we evaluated 5521 fresh frozen tumor tissues obtained from 5143 Japanese cancer patients through whole-exome sequencing (WES), cancer gene panel sequencing, fusion gene panel sequencing and microarray-based gene expression profiling (GEP).
Furthermore, we developed an in-house analytical pipeline termed "Shizuoka Multi-omics Analysis Protocol," which includes SNPs specific to Japanese individuals and data on cancer-specific gene alterations obtained from Japanese cancer patients. The present results are a part of the singlecenter study called "High-tech Omics-based Patient Evaluation" or "Project HOPE" 12 conducted at the Shizuoka Cancer Center from 2014, which aims to establish the Japanese version of The Cancer Genome Atlas (JCGA).
| MATERIAL S AND ME THODS

| Ethical statement
All experimental protocols were approved by the institutional review board at the Shizuoka Cancer Center (Authorization Number: [25] [26] [27] [28] [29] [30] [31] [32] [33] . Written informed consent was obtained from all patients for their participation in the study. All experiments using clinical samples were carried out in accordance with the approved guidelines. 13 
| Clinical samples
To identify somatic and germline genomic alterations in patients, tumor and matched normal samples were subjected to WES, comprehensive cancer panel (CCP) sequencing, fusion gene panel sequencing and GEP. These samples were obtained from patients receiving surgical treatment at the Shizuoka Cancer Center Hospital. Fresh surgical specimens were assessed by a pathologist, and samples with tumors weighing >100 mg were analyzed. Samples were not further filtered in accordance with pathophysiological features or cancer type. Blood samples from the same patients were used as the control for WES and CCP, and tumor-adjacent normal tissue specimens were used as the control for GEP. WES, CCP and fusion gene panel sequencing were performed using an Ion Proton System (Thermo Fisher Scientific) and transcriptome profiling was performed using an Agilent system (Agilent Technologies). Detailed experimental protocols have been previously described. [14] [15] [16] [17] Sequence data analysis procedures are described in Doc. S1. The mean depth of coverage in WES and CCP was 130 and 1169, respectively.
| Evaluation of driver and actionable genomic alterations
Genomic aberrations were evaluated taking into consideration driver and actionable alterations; the former refers to genomic changes contributing to tumorigenesis and the latter to those attacked by molecular-targeted drugs. These aberrations were evaluated using an analysis pipeline called "Shizuoka Multi-omics Analysis Figure S1 ). [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] Variants classified under tier 1 were considered for drivability assessment, as described below. When classifying genomic alterations based on drivability, exact matches with database entries were required. A combination of (a) chromosome number, genomic coordinates and base substitution patterns or (b) gene symbols, amino acid positions and amino acid substitution patterns were used for database matching.
Actionable mutations were classified into five evidence levels in accordance with those proposed by the Center for Cancer Genomics and Advanced Therapeutics. 28 Confidence levels of drugs (approved by a regulatory agency, clinical trial, case report or pre-clinical analysis) and the matching status of cancer types between the database and the query were used in the classification ( Figure S2 ). Such alterations, classified as level A, were defined as druggable alterations.
| Construction of a catalogue of cancer-related genes and pathway assignment
To focus on cancer driver genes, data on 914 genes including (a) oncogenes and TSGs and (b) genes harboring somatic pathogenic mutations were compiled. The former were obtained from COSMIC Cancer Gene Census, 29 OncoKB Cancer Gene List, 25 and the literature [30] [31] [32] and the latter were obtained from integrating genes with somatic pathogenic mutations reported in CGI, 18 ClinVar, 26 DoCM, 22 and OncoKB 25
and non-functional mutations in IARC-TP53. 24 Furthermore, in our analysis pipeline SMAP, 1074 cancer-related genes were compiled from 27 resources including cancer gene panels. To evaluate biological processes affected by driver and actionable alterations, genes were annotated with pathway classification in accordance with the KEGG pathway, 33 UniProt 34 and the literature, 2,31,32 followed by manual curation. Twentyseven pathways classified into 11 categories were assigned to 1462 genes (Table S1 ). The list of 1988 genes including oncogene/TSG classification and pathway information is provided in Table S2 .
| RE SULTS
| The HOPE cohort
The HOPE cohort comprised 5521 tumor specimens (5020 primary tumors and 501 metastatic tumors) derived from 5143 patients treated at the Shizuoka Cancer Center Hospital from January 2014 to March 2019. The types of cancers are summarized in Figure 3 . 
| Germline mutations for hereditary cancer syndromes
The prevalence of germline mutations causing hereditary cancer syndromes was evaluated from 3022 blood samples for which confirmatory results were available. Pathogenic mutations in 49 hereditary cancer genes with a minor allele frequency of <1% were extracted.
Germline driver mutations were detected in 9.2% of cases (279 out of 3022) in 25 genes (Table 1A) . The top 5 genes, MSH2, BRCA1, CDH1, SDHD, and APC, accounted for 57.7% of the total. Among them, 12.2%
(1.1% of total) were confirmed as pathogenic mutations using a confirmatory test and 6.1% were diagnosed as hereditary cancer syndromes. Driver mutations in these cases were detected in 14 genes, with BRCA1 being the most prominent gene in 9 cases, followed by MLH1 (5 cases), BRCA2 (4 cases), CHEK2 (3 cases), PTEN (2 cases), and SDHB (2 cases). Among 25 genes with driver mutations, 22 genes were matched to those reported by The Cancer Genome Atlas (TCGA) group. 6 These genes covered 97.5% (285 out of 293) and 39.5% (335 out of 853) of mutations in HOPE and TCGA cohorts, respectively. BRCA1, CHEK2, BRCA2, TP53, NF1, and MSH6 were commonly identified in the top 20 genes. Distinct distribution of cancer type and analysis pipeline used in both cohort contribute dataset specific mutations.
No and one kinship were observed in 34 and 279 cases, respectively, by means of family history and germline SNP analysis. In the latter, APC p.Gln2322Arg were shared by one colon and one rectal tumor sample, indicating that they belong to the same family. In the remaining 277 cases, no kinship was detected. 
| Germline mutations for non-cancerous hereditary diseases
Herein, we focused on 12 non-cancerous hereditary diseases resulting from mutations in 34 genes that are recommended to be disclosed to patients according to the guidelines of the American College of Medical Genetics and Genomics (ACMG). 36 Accordingly, 3022 blood samples were analyzed and 11 pathogenic mutations for non-neoplastic genetic diseases in 11 cases (0.4% out of 3022) were confirmed (Table 1B) 
| Prevalence of clonal hematopoiesis
Clonal hematopoiesis results from a mutation in hematopoietic stem cells, wherein the mutant clone undergoes de novo mutagenesis and potentially progresses to myelodysplastic syndrome and leukemia. 37 Because clonal hematopoiesis occurred in blood cells used as matched controls in this study, this may affect the evaluation of somatic mutations. Therefore, 3751 blood samples derived from patients with primary tumors without cancer anamnesis were subjected to analysis.
Germline SNVs identified in 880 known oncogenes and TSGs were analyzed using a previously reported method. 38 Consequently, clonal hematopoiesis was identified in 8.4% of cases (Table 2) . Upon stringent comparison, clonal hematopoiesis in 41 cases (1.1%) was identical to that reported in other studies. 7, 38 Mutated genes and their frequencies in these 41 cases included DNMT3A (18 cases), SRSF2 (5 cases), TET2 (5 cases), ASXL1 (4 cases) IDH2 (3 cases), SF3B1 (3 cases), GNAS (2 cases), JAK2 (2 cases), NRAS (1 case), TP53 (1 case), and U2AF1 (1 case).
Consistent with previous reports, clonal hematopoiesis was more frequently observed among the elderly.
| Tumor mutation burden and mutation signatures
The TMB, also referred to as mutation load, representing the number of somatic mutations per megabase, has received increasing attention owing to its potential to estimate the efficacy of responses to ICIs.
The TMB was determined for 5395 samples for which WES results were available. PanCancer analysis revealed bimodal distribution, as shown in Figure 4A . When the cutoff value was set to 20, which corresponded to 663 mutations on WES, 5.4% of samples (292 out of 5395) Further classification revealed distinct TMB distributions among cancer types ( Figure 4C ). Bimodal distribution was observed in several cancers, including brain, stomach, colon, and uterine cancer and melanoma, and the cutoff varied among these cancers. However, others revealed no clear signal in the TMB distribution to classify hypermutator phenotypes.
Further characterization of hypermutator phenotypes was performed by analyzing mutation signatures. Distinct signature profiles were observed in different cancer types ( Figure 5 ). For instance, tobacco smoking-associated signatures in lung adenocarcinoma and mismatch repair deficiency-associated hypermutation in colon and uterine cancer were identified as expected ( Figure S3 ). More detailed investigation of signatures in these cases revealed distinct predisposing factors causing this phenotype among cancer types. Such samples were characterized by an extremely high TMB and POLE signature ( Figure 5) . Samples under the POLE category were limited to colorectal and endometrial cancer and numerous mutations had accumulated owing to damaging mutations in DNA repair enzyme polymerase epsilon and these phenotypes were considered different from those in Lynch syndrome. 39 
| Characteristics of driver somatic alterations
To evaluate genomic alterations contributing to tumorigenesis, multi-omics profiling results were analyzed using SMAP (Figure 1 ).
Among 5521 samples, 4131 were available for all of the following datasets and used in the following analyses: (a) mutation dataset:
WES for tumor and blood samples and CCP for tumor samples; Figure 6 ). On average, 2.3 driver events were detected. SNV and indel yielded the highest sample coverage (62.2%), followed by expression aberrations (21.0%) and gene fusions (12.9%). Two or three types of alterations were observed in 13.0% of samples. The frequency of samples with driver alterations varied among cancer types, with the highest detection rate observed in rectal cancer (95.3%), followed by colon cancer (92.2%), uterine cancer (86.9%), and GIST (84.3%), and the lowest rate observed in kidney cancer (11.7%) ( Figure 6 ). Furthermore, the relative frequency of the three alteration types differed Breast (3), rectum (2), GIST (1), lung (1), ovary (1), pleura (1)
Colon (4), stomach (1)
Breast (2), colon (1), head and neck (1)
Breast (1), lung (1), rectum (1)
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SDHB 2
Breast (1), head and neck (1)
Colon (1), uterus (1) For ovarian cancer, enrichment of these genes in the HOPE dataset reflected a distinct subtype composition (Table S3 ). Driver mutations in CTNNB1 were observed in endometrioid cancer and KRAS and PIK3CA were identified in multiple subtypes. In contrast, driver mutations in these genes were observed less frequently in serous ovarian cancer, which constitutes 100%
and 18% (15 out of 83 samples) of ovarian cancers in TCGA and HOPE, respectively. 
| Actionable genomic alterations associated with molecular-targeted drugs
The association between somatic alterations and moleculartargeted drugs was classified into five evidence levels (levels A-E). and HGMD were considered germline driver alterations. To make the results more understandable for medical staff, pathway classification of driver genes was integrated into SMAP; 92.7% of driver genes (847 out of 914) were classified into 26 pathways (Table S1 ).
Regarding SNPs in Japanese individuals, 15% of variants were specific to Japanese individuals among 26 populations, thus deterring the analysis of the clinical significance of genetic alterations.
Therefore, for more reliable annotation, iJGVD 40 and HGVD 41 were In terms of TMB, 5.4% of samples were classified as hypermutator with a cutoff value ≥20 on PanCancer analysis ( Figure 4A,B) . The present study shows that the general features of The Cancer Genome Atlas do not significantly differ between Japanese and Caucasian populations, except for racial SNPs.
However, in some certain cancer types, clear racial differences in the incidence of driver genes were observed upon comparative analysis of HOPE and TCGA datasets ( Figure S6 
